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The family of glucose transporters (GLUTs) embraces a group of isoforms of trans-membrane 
channel-proteins which allows the entry of D-glucose into the cells. These isoforms differ for 
localization and for substrate affinity. Isoform GLUT-1 was the object of this thesis, since it 
was found to be overexpressed in carcinoma cells, and it is the main responsible for the 
entrance of D-glucose into the central nervous system. The over-expression of this protein on 
the tumor cells membranes allows this type of cells to accumulate and use a large amount of D-
glucose and, consequently, to produce enough energy for their survival. In fact, tumor cells 
predominantly produce energy by a high rate of glycolysis, followed by lactic acid fermentation 
in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of 
pyruvate in mitochondria, such as that occurring in most normal cells. This metabolic switch is 
known as the Warburg Effect. Thus, selective inhibitors of GLUT1, may represent valid 
anticancer agents that selectively counteract tumor glycolysis.  
So far, several molecules have been reported to be able to block glucose uptake. Most of them 
are natural molecules such as flavonoids, flavones, chalcones, but there are also examples of 
synthetic molecules, such as tamoxifen, fulvestrant, 17-β-estradiol. The interesting thing is that 
the majority of these molecules are also active on estrogen receptor beta (ERβ). Based on this 
concept, some salycilaldoxime and salicylketoxime derivatives, that had been previously 
designed and synthetized as potential ERβ-ligands in the research group where I have carried 
out my thesis project, were also tested in cellular assays on GLUT-1, and some of them 
displayed good inhibitory activities on glucose uptake.  
The recent crystallization (resolution 2.9 Å) of the xylose transporter of E. Coli, XyLE, 
coordinated with D-glucose provided a valid starting point for a more accurate analysis of 
human GLUT1 and to study the putative interaction modes of the most active salycilketoxime 
molecules and flavonoids. This transporter is formed by 492 amino acids and its folder was 
carried out with the homology model made with online server HHpred. This model showed that 
protein GLUT1 is formed by 12 transmembranes and 4 intracellular helices and both the N-
terminus and C-terminus are located in the intracellular part of the protein. The aqueous 
channel seems to be divided into two parts by two residues that form a gate in the middle of the 
channel: Trp388 and His154. The homology model so obtained was inserted in a lipid bilayer 
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) built with software VMD to 
simulate the biological environment. The resulting complex underwent a molecular dynamic 
simulation using AMBER 11, to remove all the constraints given by the crystallization process 
and to evaluate conformational changes that happened when the complex was heated. As the 
complex was refined, the analysis of the putative binding sites for D-glucose, for the most 
active ketoximes PGL12 and PGL14 (Figure 1), and for flavonoid Myrcetin was carried out 
with docking programs GOLD and GLIDE. This analysis gave three putative binding sites: one 
situated in the extracellular portion of the channel, one situated in the middle of the channel and 
the last one located between the intracellular helices of the protein. The best binding pose for 
each ligand in each putative binding site was submitted to a molecular dynamic simulation to 
evaluate the interactions energy (using the AMBER 11 functionality MMPB(GB)SA) and the 
hydrogen bonds (using AMBER 11 functionality PTRAJ). The trajectories resulting from the 
dynamic process were also analysed with USCF CHIMERA to evaluate hydrophobic 
interaction. From the crossing of all these results, the best putative binding site for all the 
studied inhibitors was the intracellular site. A steered molecular dynamic simulation was also 
run to evaluate the putative pathway of D-glucose through the channel. 
 
Considering the pharmacophoric features required to have a good inhibitory activity on 
GLUT1, some substitutions were made on the starting hits PGL12 and PGL14 to evaluate how 
these changes might influence the inhibitory activity.  
 
    
PGL12: R1 = OH, R2 = F 
PGL14: R1= OH, R2 = H 
 
Figure 1. Salicylketoxime GLUT1-inhibitors PGL12 and PGL14 
       
My project was dedicated to study the introduction of various substituents in the phenolic ring. 
The synthesis of these analogues started from commercial product 3-bromophenol, which was 
carbamoylated on the hydroxyl group. Then, a remarkably regioselective ortho-lithiation 
process, followed by a quenching with hexachloroethane, produced the insertion of a chlorine 
atom in position 2. The corresponding 2-chloro-3-bromo-carbamoylphenol was hydrolysed 
under basic conditions, to obtain 3-bromo-2-chloro-phenol. This molecule was acetylated and 
than the acetyl group was transposed by a Fries rearrangement reaction to afford 3-bromo-2-
chloro-6-acetylphenol. This molecule underwent a cross-coupling reaction under Suzuki 
conditions using different boronic-acids to obtain variously substituted ketone intermediates. 
The metoxy group, if present in the aryl substituent, was deprotected with BBr3 in CH2Cl2 and 
the ketone group was finally transformed into the desired ketoxime . (Figure 2.) 
 
 
 
 
 
Figure 2. General synthetic pathway  
 
